Stock KALV KALVISTA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
11.67 USD +3.73% Intraday chart for KalVista Pharmaceuticals, Inc. +3.27% -4.73%
May. 31 Sector Update: Health Care Stocks Higher Late Afternoon MT
May. 31 Sector Update: Health Care MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sector Update: Health Care Stocks Higher Late Afternoon
Sector Update: Health Care
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise
Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
Kalvista Pharmaceuticals Insider Sold Shares Worth $258,337, According to a Recent SEC Filing
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals : Corporate Presentation May 2024
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors
Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
Certain performance stock options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
Certain restricted stock units of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
Certain Stock Options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KALV Stock
  4. News KalVista Pharmaceuticals, Inc.
  5. Other languages